Company: LENZ
Filing Date: 2025-04-14
Form Type: 424B3
Source: 0001628280-25-017694
Chunk: 7

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-14
Form: 424B3
Chunk 7
---
 Common Stock, consisting of (i) 12,922,451 shares of Common Stock held by the selling securityholders and (ii) 147,642 shares of Common Stock issuable upon the exercise of outstanding warrants held by the selling securityholders. |
| Use of Proceeds                          |     | We will not receive any proceeds from the sale of our shares of common stock offered by the selling securityholders under this prospectus (the “Securities”). See the section titled “Use of Proceeds” appearing elsewhere in this prospectus for more information.        |
| Common Stock Outstanding                 |     | 27,531,490 shares of Common Stock as of December 31, 2024.                                                                                                                                                                                                                 |
| Risk Factors                             |     | See the section titled “Risk Factors” and other information included in this prospectus and the documents incorporated by reference for a discussion of factors that you should consider carefully before deciding to invest in our Common Stock.                          |
| Nasdaq symbol                            |     | “LENZ” for our Common Stock.                                                                                                                                                                                                                                               |

The number of shares of Common Stock outstanding is based on 27,531,490 shares of Common Stock as of December 31, 2024 and excludes the following, in each case as of December 31, 2024: • 164,676 shares of our Common Stock issuable upon the exercise of warrants to purchase shares of our Common Stock outstanding as of December 31, 2024, with an exercise price of $10.64 per share; • 1,458,939 shares of our Common Stock issuable upon the exercise of outstanding options under the LENZ OpCo 2020 Equity Incentive Plan (the “2020 Plan”) as of such date, which were assumed by the Company in connection with the Merger, with a weighted average exercise price of $4.28 per share; • 8,438 shares of our Common Stock issuable upon the exercise of outstanding options under the LENZ Therapeutics, Inc. (f/k/a Graphite Bio, Inc.) 2021 Stock Option and Incentive Plan as of such date, with a weighted average exercise price of $11.94 per share; • 1,522,550 shares of our Common Stock issuable upon the exercise of outstanding options under the LENZ Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) as of such date, with a weighted average exercise price of $16.45 per share